Results 101 to 110 of about 3,056 (181)

Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? [PDF]

The amyloid cascade hypothesis for Alzheimer’s disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis’ claim that the protein amyloid-beta is the cause of the disease.
Alavi, Abass, Poul F. Høilund-Carlsen, Perry, George, Mona-Elisabeth Revheim, Neve, Rachael L., Revheim, Mona Elisabeth, Barrio, Jorge R., George Perry, Jorge R. Barrio, Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Rudolph J. Castellani, Rachael L. Neve, Abass Alavi, Castellani, Rudolph J.   +14 more
core   +1 more source

Comparative Safety Profiles of Anti-Amyloid Therapies in Early Alzheimer’s Disease (AD): A Detailed Systematic Review and Meta-Regression Analysis of Amyloid Related Imaging Abnormalities (ARIA) – Incidence and Infusion Reactions for Lecanemab, Donanemab, and Aducanumab

BJPsych Open
Aims: Alzheimer’s disease continues to be a huge health concern around the globe. Although similar recent developments in anti-amyloid therapy are promising, there is concern about some side effects like ARIA.
Sathyan Soundara Rajan, Sneh Babhulkar, Gaurav Uppal, Sharmi Bhattacharyya, Asha Devi Dhandapani   +4 more
doaj   +1 more source

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

Alzheimer’s disease (AD), the leading cause of dementia, is a multifaceted neurodegenerative disorder characterized by amyloid-beta (Aβ) aggregation, tau pathology, and neuroinflammation.
Abdul Raheem, Syed Muhammad Sinaan Ali, Taha basit Ameen, Omme Salma, Umair Ali, Mashooque Ali, Syed Muhammad Iraj Abbas, Syeda Naveera Kashif, Muhammad Arif Arifi, Muhammad Abdul Samee, Maher Khowaja   +10 more
core   +1 more source

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Grimmer T.
europepmc   +1 more source

Donanemab in treating Alzheimer’s disease

Alzheimerin tautia sairastaa yli 50 miljoonaa ihmistä ympäri maailman. Se on muistisairaus, jonka taudinkuvaan kuuluu hiljalleen etenevä, laajakirjoinen kognitiivisen tason ja toimintojen alenema. Usein oireistoon liittyy myös erilaisia neuropsykiatrisia
Junnikkala, Helvi
core  

Considerações do Departamento de Psicogeriatria da ABP sobre a aprovação e uso clínico do donanemabe na doença de Alzheimer pela ANVISA [PDF]

The Department of Psychogeriatrics, after critical analysis of pivotal studies and recent scientific literature, issues the following considerations on the approval and clinical use of donanemab, a monoclonal antibody targeting beta-amyloid, for ...
Luna, Juliano Victor Albuquerque, Pereira, Lucas Alves, Berger, Aline Kives, Bussolo, Alan Goulart, Alves, Gilberto Sousa, Toledo, Maria Alice de Vilhena, Nicolato, Rodrigo, da Silva, Antônio Geraldo, Borges, Marcus Kiiti, Allevato , Marcelo, Aguiar, Carlos Clayton Torres, Martins, Claudio Meneghello, Ferreira, Ricardo Barcelos, Stoppe Junior, Alberto, Cruz, Nairton Lopes, Alves, Tania Correa de Toledo Ferraz   +15 more
core  

Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]

eNeuro
McDiarmid A.
europepmc   +1 more source

Are lecanemab and donanemab disease‐modifying therapies?

Alzheimer's & Dementia
Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo   +2 more
openaire   +2 more sources

Donanemab Infusion and Recurrent Seizures in a Patient With Alzheimer's Disease and Epilepsy in the Absence of Amyloid-Related Imaging Abnormalities (ARIA). [PDF]

Cureus
Espinosa PS, Li S, Preisler J, Hennekens CH.   +3 more
europepmc   +1 more source

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab. [PDF]

Neurocase
Schwartz NU, Dietz CD, Lin Z, Tammewar G, Bui N, La Joie R, Wang Y, Sreekrishnan A, Suhami D, VandeVrede L, Ljubenkov PA, Rojas JC.   +11 more
europepmc   +1 more source